The management of critically ill patients with end-stage liver disease can be challenging due to the vulnerability of this population and the wide-ranging complications of the disease. This review proposes an approach based on the major organ systems affected, to provide a framework for managing the most common complications. Although considerable practice variation exists, a focus on the evidence behind the most common practices will ensure the development of the optimal skillset to appropriately manage this disease.
FindlayJYFixOKPaugam-BurtzC. Critical care of the end-stage liver disease patient awaiting liver transplantation. Liver Transpl. 2011;17
(5):496–510.
2.
SaidAWilliamsJHoldenJ. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004;40
(6):897–903.
3.
DasVBoellePYGalboisA. Cirrhotic patients in the medical intensive care unit: early prognosis and long-term survival. Crit Care Med. 2010;38
(11):2108–2116.
4.
LimYSKimWR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis. 2008;12
(4):733–746.
5.
WehlerMKokoskaJReulbachUHahnEGStraussR. Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology. 2001;34
(2):255–261.
6.
BustamanteJRimolaAVenturaPJ. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30
(5):890–895.
7.
FerenciPLockwoodAMullenKTarterRWeissenbornKBleiAT. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35
(3):716–721.
8.
YunBCKimWRBensonJT. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology. 2009;49
(5):1610–1615.
9.
PrakashRMullenKD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7
(9):515–525.
10.
QureshiMOKhokharNShafqatF. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2014;24
(3):160–163.
11.
ShawcrossDLSharifiYCanavanJB. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol. 2011;54
(4):640–649.
12.
TripodiAMannucciPM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365
(2):147–156.
13.
YoussefWISalazarFDasarathySBeddowTMullenKD. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol. 2003;98
(6):1391–1394.
14.
British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122
(1):10–23.
15.
RiordanSMWilliamsR. Treatment of hepatic encephalopathy. N Engl J Med. 2010;362
(12):1140–1142.
16.
PhongsamranPVKimJWCupo AbbottJRosenblattA. Pharmacotherapy for hepatic encephalopathy. Drugs. 2010;70
(9):1131–1148.
17.
Als-NielsenBGluudLLGluudC. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328
(7447):1046.
18.
ShawcrossDJalanR. Dispelling myths in the treatment of hepatic encephalopathy. Lancet. 2005;365
(9457):431–433.
19.
CordobaJLopez-HellinJPlanasM. Normal protein diet for episodic hepatic encephalopathy. J Hepatol. 2004;41
(1):38–43.
20.
VaqueroJChungCCahillMEBleiAT. Pathogenesis of hepatic encephalopathy in acute liver failure. Semin Liver Dis. 2003;23
(3):259–269.
21.
XueTQiuJHQiaoL. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(25):2424; author reply2424–2425.
22.
MaclaytonDOEaton-MaxwellA. Rifaximin for treatment of hepatic encephalopathy. Ann Pharmacother. 2009;43
(1):77–84.
23.
WuDWuSMLuJZhouYQXuLGuoCY. Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy: a meta-analysis. Gastroenterol Res Pract. 2013;2013:236963.
24.
SharmaBCSharmaPLuniaMKSrivastavaSGoyalRSarinSK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108
(9):1458–1463.
25.
NeffGWKemmerNDuncanCAlsinaA. Update on the management of cirrhosis–focus on cost-effective preventative strategies. Clinicoecon Outcomes Res. 2013;5:143–152.
26.
CashWJMcConvillePMcDermottEMcCormickPACallenderMEMcDougallNI. Current concepts in the assessment and treatment of hepatic encephalopathy. QJM. 2010;103
(1):9–16.
27.
Blanco VelaCIPoo RamírezJL. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Ann Hepatol. 2011;10
(suppl 2):S55–S59.
28.
GrimmGFerenciPKatzenschlagerR. Improvement of hepatic encephalopathy treated with flumazenil. Lancet. 1988;2
(8625):1392–1394.
29.
LockBGPanditK. Is flumazenil an effective treatment for hepatic encephalopathy?Ann Emerg Med. 2006;47
(3):286–288.
30.
BolognesiMSacerdotiDPascoliMD. Haeme oxygenase mediates hyporeactivity to cirrhotic rats with ascites phenylephrine in the mesenteric vessels of rats with ascites. Gut. 2005;54
(11):1630–1636.
31.
PiscagliaFZironiGGaianiS. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology. 1999;30
(1):58–64.
32.
Pérez-PeñaJRincónDBañaresR. Autonomic neuropathy in end-stage cirrhotic patients and evolution after liver transplantation. Transplantat Proc. 2003;35
(5):1834–1835.
33.
AtesFTopalEKosarF. The relationship of heart rate variability with severity and prognosis of cirrhosis. Dig Dis Sci. 2006;51
(9):1614–1618.
34.
MøllerSHenriksenJH. Cardiovascular complications of cirrhosis. Gut. 2008;57
(2):268–278.
35.
PellicoriPTorromeoCCalicchiaA. Does cirrhotic cardiomyopathy exist? 50 years of uncertainty. Clin Res Cardiol. 2013;102
(12):859–864.
WardCAMaZLeeSSGilesWR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol. 1997;273
(2 pt 1):G537–G544.
38.
NaschitzJESlobodinGLewisRJZuckermanEYeshurunD. Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J. 2000;140
(1):111–120.
39.
ThalheimerUBurroughsAK. Bacterial translocation and cardiovascular complications of cirrhosis. Gut. 2008;57
(8):1181;1181–1182.
40.
JeppesenJBMortensenCBendtsenFMøllerS. Lactate metabolism in chronic liver disease. 2013;73
(4):293–299.
41.
AlmenoffPLLeavyJWeilMHGoldbergNBVegaDRackowEC. Prolongation of the half-life of lactate after maximal exercise in patients with hepatic dysfunction. Crit Care Med. 1989;17(9):870–873.
42.
WollPJRecordCO. Lactate elimination in man: effects of lactate concentration and hepatic dysfunction. Eur J Clin Invest. 1979;9
(5):397–404.
43.
CasaburiROiS. Effect of liver disease on the kinetics of lactate removal after heavy exercise. Eur J Appl Physiol Occup Physiol. 1989;59
(1-2):89–97.
44.
StrawitzJoseph GeorgeNormanGrossblatt, eds. Septic Shock: Proceedings of a Workshop. Washington: National Academy of Sciences-National Research Council; 1965.
45.
NguyenHBRiversEPKnoblichBP. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock*. Crit Care Med. 2004;32
(8):1637–1642.
46.
McNelisJMariniCPJurkiewiczA. Prolonged lactate clearance is associated with increased mortality in the surgical intensive care unit. Am J Surg. 2001;182
(5):481–485.
47.
MiddletonPKellyAMBrownJRobertsonM. Agreement between arterial and central venous values for pH, bicarbonate, base excess, and lactate. Emerg Med J. 2006;23
(8):622–624.
48.
GallagherEJRodriguezKTougerM. Agreement between peripheral venous and arterial lactate levels. Ann Emerg Med. 1997;29
(4):479–483.
49.
ShapiroNIHowellMDTalmorD. Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med. 2005;45
(5):524–528.
50.
SoodGFallonMBNiwasS. Utility of a dyspnea-fatigue index for screening liver transplant candidates for hepatopulmonary syndrome. Hepatology. 1998;28(suppl):742A.
51.
FallonMBAbramsGA. Pulmonary dysfunction in chronic liver disease. Hepatology. 2000;32
(4):859–865.
52.
MandellMercedes SusanMasahikoTaniguchi. Pulmonary complications of liver disease. Liver Anesthesiol Crit Care Med. Springer New York, 2012. 255–266.
53.
Al-KhafajiA1HuangDT. Critical care management of patients with end-stage liver disease. Crit Care Med. 2011;39
(5):1157–1166.
54.
AbramsGAJaffeCCHofferPBBinderHJFallonMB. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology. 1995;109
(4):1283–1288.
55.
LangePAStollerJK. The hepatopulmonary syndrome. Ann Intern Med. 1995;122
(7):521–529.
56.
FallonMBAbramsGA. Pulmonary dysfunction in chronic liver disease. Hepatology. 1995;122
(7):521–529.
57.
LangePAStollerJK. The hepatopulmonary syndrome: effect of liver transplantation. Clin Chest Med. 1996;17
(1):115–123.
58.
KrowkaMJDicksonERCorteseDA. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest. 1993;104
(2):515–521.
59.
AndrivetPCadranelJHoussetBHerigaultRHarfAAdnotS. Mechanisms of impaired arterial oxygenation in patients with liver cirrhosis and severe respiratory insufficiency. effects of indomethacin. Chest. 1993;103
(2):500–507.
60.
SchenkPMadlCRezaie-MajdSLehrSMüllerC. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med. 2000;133
(9):701–706.
61.
ParameshASHusainSZShneiderB. Improvement of hepatopulmonary syndrome after transjugular intrahepatic portasystemic shunting: case report and review of literature. Pediatr Transplant. 2003;7
(2):157–162.
62.
LaschHMFriedMWZacksSL. Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome. Liver Transpl. 2001;7
(2):147–149.
63.
HoeperMMKrowkaMJStrassburgCP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004;363
(9419):1461–1468.
64.
ColleIOMoreauRGodinhoE. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37
(2):401–409.
65.
KrowkaMJPlevakDJFindlayJYRosenCBWiesnerRHKromRA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 2000;6
(4):443–450.
66.
KrowkaMJMandellMSRamsayMA. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl. 2004;10
(2):174–182.
67.
HumbertMSitbonOSimonneauG. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351
(14):1425–1436.
68.
ReichenbergerFVoswinckelRStevelingE. Sildenafil treatment for portopulmonary hypertension. Eur Respir J. 2006;28
(3):563–567.
69.
ChuaRKeoghAMiyashitaM. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transpl. 2005;24
(4):498–500.
70.
LazaridisKNFrankJWKrowkaMJKamathPS. Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med. 1999;107
(3):262–267.
71.
LiebermanFLHidemuraRPetersRLReynoldsTB. Pathogenesis and treatment of hydrothorax complicating cirrhosis with ascites. Ann Intern Med. 1966;64
(2):341–351.
72.
AlbertsWMSalemAJSolomonDABoyceG. Hepatic hydrothoraxcause and management. Arch Intern Med. 1991;151
(12):2383–2388.
StraussRMMartinLGKaufmanSLBoyerTD. Transjugular intrahepatic portal systemic shunt for the management of symptomatic cirrhotic hydrothorax. Am J Gastroenterol. 1994;89
(9):1520–1522.
76.
GordonFDAnastopoulosHTCrenshawW. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology. 1997;25
(6):1366–1369.
77.
ArroyoVGinèsPGerbesAL. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23
(1):164–176.
78.
FogelMRSawhneyVKNealEAMillerRGKnauerCMGregoryPB. Diuresis in the ascites patient: a randomized controlled trial of three regimens. J Clin Gastroenterol. 1981;3
(suppl 1):73–80.
79.
GinèsPArroyoVQuinteroE. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology. 1987;93
(2):234–241.
80.
GinésPArroyoVQuinteroE. Management of cirrhosis and ascites. N Engl J Med. 1987;93
(2):234–241.
81.
Garcia-TsaoG. Treatment of refractory ascites: tips or taps?Hepatology. 2001;33
(2):477–479.
82.
Garcia-TsaoGBoschJ. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362
(9):823–832.
83.
GarciaTsaoGSanyalAJGraceNDCareyW, Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Com mittee of the American College of Gastro enterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:92238.
84.
BurroughsAKMcCormickPAHughesMDSprengersDD'HeygereFMcIntyreN. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. Gastroenterology. 1990;99
(5):1388–1395.
85.
BoschJBerzigottiAGarciaPaganJCAbraldesJG. The management of por tal hypertension: rational basis, available treatments and future options. J Hepatol. 2008;48(suppl 1):S68S92.
86.
JaimeBJuan CarlosGarcía-Pagán. Complications of cirrhosis. I. Portal hypertension. J Hepatol. 2000;32
(suppl 1):141–156.
87.
Garcia-TsaoGSanyalAJGraceND. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46
(3):922–938.
88.
AngelicoMCarliLPiatCGentileSCapocacciaL. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology. 1997;113
(5):1632–1639.
89.
VillanuevaCColomoABoschA. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368
(1):11–21.
90.
CarbonellNPauwelsASerfatyLFourdanOLévyVGPouponR. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40
(3):652–659.
91.
BañaresRAlbillosARincónD. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: A meta-analysis. Hepatology. 2002;35
(3):609–615.
92.
CalèsPMasliahCBernardB. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med. 2001;344
(1):23–28.
93.
SassDAChopraKB. Portal hypertension and variceal hemorrhage. Med Clin North Am. 2009;93
(4):837–853.
CorleyDACelloJPAdkissonWKoWFKerlikowskeK. Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology. 2001;120
(4):946–954.
96.
AbidSJafriWHamidS. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. Am J Gastroenterol. 2009;104
(3):617–623.
CooperGSChakAWayLEHammarPJHarperDLRosenthalGE. Early endoscopy in upper gastrointestinal hemorrhage: associations with recurrent bleeding, surgery, and length of hospital stay. Gastrointest Endosc. 1999;49
(2):145–152.
99.
CheungJSooIBastiampillaiRZhuQMaM. Urgent vs. non-urgent endoscopy in stable acute variceal bleeding. Am J Gastroenterol. 2009;104
(5):1125–1129.
100.
TerblancheJNorthoverJMBornmanP. A prospective controlled trial of sclerotherapy in the long term management of patients after esophageal variceal bleeding. Surg Gynecol Obstet. 1979;148
(3):323–333.
101.
StiegmannGVGoffJSMichaletz-OnodyPA. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med. 1992;326
(23):1527–1532.
102.
TerblancheJBornmanPCKahnD. Failure of repeated injection sclerotherapy to improve long-term survival after oesophageal variceal bleeding: a five-year prospective controlled clinical trial. Lancet. 1983;2
(8363):1328–1332.
103.
Soares-WeiserKBrezisMTur-KaspaRLeiboviciL. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Cochrane Database Syst Rev. 2002;(2):CD002907.
104.
BernardBGrangeJDKhacENAmiotXOpolonPPoynardT. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29
(6):1655–1661.
105.
RimolaAGarcía-TsaoGNavasaM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32
(1):142–153.
106.
FernándezJRuiz del ArbolLGómezC. Norfloxacin vs Ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006;131
(4):1049–1056.
107.
CabreraJMaynarMGranadosR. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology. 1996;110
(3):832–839.
108.
García-PagánJCCacaKBureauC. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362
(25):2370–2379.
109.
LaBergeJMSombergKALakeJR. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology. 1995;108
(4):1143–1151.
110.
VlavianosPGimsonAEWestabyDWilliamsR. Balloon tamponade in variceal bleeding: use and misuse. BMJ. 1989;298
(6681):1158.
GinèsAEscorsellAGinèsP. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology. 1993;105
(1):229–236.
113.
DavenportAAhmadJAl-KhafajiAKellumJAGenykYSNadimMK. Medical management of hepatorenal syndrome. Nephrol Dial Transplantat. 2012;27(1):34–41.
114.
ArroyoVGinèsPGerbesAL. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23
(1):164–176.
115.
GinèsPSchrierRW. Renal failure in cirrhosis. N Engl J Med. 2009;361
(13):1279–1290.
116.
AssimakopoulosSFThomopoulosKCLabropoulou-KaratzaC. Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome?World J Gastroenterol. 2009;15
(25):3194–3195.
117.
AkriviadisEBotlaRBriggsWHanSReynoldsTShakilO. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119
(6):1637–1648.
BrannOS. Infectious complications of cirrhosis. Curr Gastroenterol Rep. 2001;3
(4):285–292.
121.
SauneufBChampigneulleBSoummerA. Increased survival of cirrhotic patients with septic shock. Crit Care. 2013;17
(2):R78.
122.
KingPD. Infectious complications of liver disease. J Gen Intern Med. 1993;8
(6):327–332.
123.
HoefsJohn C. Spontaneous bacterial peritonitis. Hepatology. 1982;2(4):399S–407S.
124.
SortPNavasaMArroyoV. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341
(6):403–409.
125.
RunyonBA, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis. Hepatology. 2004;39
(3):841–856.
126.
TitóLRimolaAGinèsPLlachJArroyoVRodésJ. Recurrence of spontaneous bacteria peritonitis in cirrhosis: frequently and predictive factors. Hepatology. 1988;8
(1):27–31.
127.
DellingerRPLevyMMRhodesA. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2013;39
(2):165–228.
128.
GustotTDurandFLebrecDVincentJLMoreauR. Severe sepsis in cirrhosis. Hepatology. 2009;50
(6):2022–2033.
129.
RussellJAWalleyKRSingerJ. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358
(9):877–887.
130.
FernándezJEscorsellAZabalzaM. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology. 2006;44
(5):1288–1295.
131.
DellingerRPLevyMMRhodesA. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39
(2):165–228.
132.
PughRNMurray-LyonIMDawsonJL. Transection of the oesophagus for bleeding oesophageal varicose. Br J Surg. 1973;60:646.
